Enterococcus faecium
Enterococcus faecium (undesignated strain) appears in the research literature primarily in the context of antibiotic resistance and hospital-associated infection rather than probiotic applications. The available papers describe mechanisms of vancomycin and beta-lactam resistance, virulence factor production, mobile genetic elements, and global dissemination of hospital clones — reflecting E. faecium's status as a significant opportunistic pathogen in healthcare settings. This entry represents the species-level taxonomy rather than a specific characterized probiotic strain; without a designated strain identifier, this organism should be described in terms of its taxonomic and research context rather than in probiotic-benefit framing.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 233 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 38 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
811 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 32656217 →Randomized, Placebo-Controlled, Double-Blind and Open-Label Studies in the Treatment and Prevention of Acute Diarrhea With Enterococcus faecium SF68· Frontiers in Medicine · 2020
-
[2]
PMID 30969170 →Enterococcus faecium secreted antigen A generates muropeptides to enhance host immunity and limit bacterial pathogenesis· eLife · 2019
-
[3]
PMID 29633645 →Enterococcus faecium SF68 as a model for efficacy and safety evaluation of pharmaceutical probiotics· Beneficial Microbes · 2018
-
[4]
PMID 28676009 →Aging Eye Microbiota in Dry Eye Syndrome in Patients Treated with Enterococcus faecium and Saccharomyces boulardii· Current Clinical Pharmacology · 2017
-
[5]
PMID 21831763 →The influence of probiotic Enterococcus faecium strain L5 on the microbiota and cytokines expression in rats with dysbiosis induced by antibiotics· Beneficial Microbes · 2010
-
[6]
PMID 16026136 →One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels.· PubMed · 2005
-
[7]
PMID 11642232 →Transient Intestinal Carriage after Ingestion of Antibiotic-Resistant Enterococcus faecium from Chicken and Pork· New England Journal of Medicine · 2001
-
[8]
PMID 11200372 →Impact on Human Intestinal Microflora of an Enterococcus faecium Probiotic and Vancomycin· Scandinavian Journal of Infectious Diseases · 2000
-
[9]
PMID 8530808 →Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1–2 hepatic encephalopathy· Journal of Hepatology · 1995